Sleep Peptide · Circadian

DSIP: Delta Sleep-Inducing Peptide

A UK-focused, evidence-based comparison of DSIP and Dihexa — mechanism, benefits, dosing, side effects, legal status, and stacking.

Delta Sleep-Inducing Peptide (DSIP) is a 9-amino-acid peptide isolated in 1977 by the laboratory of Schoenenberger and Monnier at the University of Bern from the cerebral venous blood of rabbits in artificially-induced electroencephalographic delta sleep states. Sequence: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. Despite its evocative name and 45+ years of research, DSIP has never been registered as a sleep medicine in any major market, and its precise mechanism remains incompletely characterised. It is sold widely in the research-chemical space for sleep architecture support, stress modulation, and circadian rhythm work, with a small but enduring following in the bio-hacker community.

What is DSIP?

DSIP is a short linear peptide originally isolated as the putative endogenous mediator of slow-wave (delta) sleep, though its endogenous status and physiological role have been debated for decades. Synthetic DSIP is widely available as a lyophilised research-chemical powder for reconstitution and subcutaneous, intramuscular, or intranasal administration. The compound has been the subject of approximately 100-150 published peer-reviewed papers spanning the late 1970s through the present, covering sleep architecture, EEG effects, stress modulation, opioid withdrawal, and a number of more speculative indications. No biopharmaceutical has progressed DSIP through Western Phase 2+ clinical trials despite the long research history; the relative simplicity of the peptide and its lack of patent protection are likely contributors.

Chemistry: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu · 9-mer · MW 848.81 g/mol
Origin: Schoenenberger / Monnier laboratory, University of Bern (Switzerland), isolated 1977
Primary route: Subcutaneous or intramuscular; intranasal occasionally reported
Pharmacokinetics: Very short plasma half-life (minutes) but reported functional sleep and circadian effects across the night of administration.
Class: Sleep-modulating nonapeptide

Mechanism of Action

DSIP's precise molecular target remains uncharacterised — no clearly defined receptor has been identified despite decades of investigation. Proposed mechanisms include: modulation of GABAergic and serotonergic transmission in sleep-regulatory brain regions (suprachiasmatic nucleus, ventrolateral preoptic area); buffering of corticotropin-releasing hormone (CRH) activity, reducing stress-driven arousal; modulation of opioid receptor function (proposed mechanism for the reported opioid-withdrawal benefit); and antioxidant effects reducing reactive oxygen species in brain tissue. The functional profile in EEG studies is to increase slow-wave sleep proportion and reduce sleep latency, though effects in healthy subjects are modest and variable. The mechanism story is the weakest in this list of peptides — 45 years of research has not converged on a defined receptor.

Proposed Benefits

Reported benefits cluster around sleep and stress: increased slow-wave (delta) sleep proportion, reduced sleep latency, improved sleep continuity, reduced subjective insomnia, normalisation of disrupted circadian rhythm (jet lag, shift work), reduced anxiety and stress-driven arousal, and a small literature on opioid withdrawal symptom reduction. Some users report improved next-day mental clarity and mood after a single bedtime dose, consistent with improved sleep architecture. Russian and Eastern European clinical literature includes small trials in chronic insomnia, withdrawal from opioids and alcohol, and stress-related disorders. The effect size in healthy subjects is modest — DSIP is not a hypnotic in the sense of a benzodiazepine or zolpidem, and users seeking strong sleep induction will not find it here. Its niche is sleep quality, not sleep onset speed.

Evidence Base

The literature is large in volume but methodologically variable. Key references: Monnier et al. 1977 (original isolation paper, EBP/PNAS); Schoenenberger 1984 (review of clinical applications); Yehuda and Mostofsky 1998 (broad pharmacological review); Sudakov et al. various (Russian clinical trials in withdrawal contexts); Kostadinov 2017 (modern review). The strongest signals are EEG effects on slow-wave sleep architecture and some clinical effect in withdrawal contexts. Independent Western replication of clinical efficacy is limited. No Phase 3 or registration-grade trials have been completed, and DSIP has not been pursued by any major biopharmaceutical despite the long research history.

Dosage & Administration

No medically approved dose exists. Community protocols typically use 100-200 µg subcutaneously, 30-60 minutes before sleep. Some users report better results with intranasal administration (faster onset). Daily use is not generally recommended; intermittent use (2-3 times per week) or short courses (10-14 days) are more commonly reported. Reconstitute lyophilised powder with bacteriostatic water and refrigerate. The peptide is relatively low-dose compared to compounds like TB-500 — at 100-200 µg per dose, a 2 mg vial provides 10-20 doses. Higher daily doses (1-2 mg) are sometimes reported but offer no clear advantage over the low-dose evening protocol and may cause unwanted daytime sedation.

This is a community-reported protocol summary, not a medical recommendation. There is no established human dose. Consult a qualified healthcare professional before using any research compound.

Side Effects & Risks

DSIP has a clean reported safety profile across the published literature. Acute side effects are rare and mild: occasional next-morning grogginess (suggesting too high a dose or too late timing), vivid dreams, mild headache. No documented dependence or tolerance with intermittent use. The peptide does not appear to be addictive and there is no reported withdrawal syndrome. Contraindications: pregnancy/breastfeeding (no safety data), known peptide hypersensitivity. There is no documented interaction with common sleep medications, but caution applies to combinations with benzodiazepines, Z-drugs (zolpidem etc.), or sedating antihistamines — theoretical additive sedation. The compound is sometimes used in opioid withdrawal protocols under medical supervision; self-managed use in addiction contexts is not advised.

UK Legal Status

UK: not a controlled substance, not licensed by MHRA, not scheduled under the Psychoactive Substances Act. Legal as a research chemical for laboratory use. WADA: DSIP is not on the Prohibited List as of the 2026 update. US: not FDA-approved; sold as a research chemical in the same grey-area context as other peptides. No country has DSIP registered as a sleep medicine despite its 45-year research history.

DSIP vs Dihexa

DSIP and Dihexa address entirely different goals. DSIP is a sleep and stress modulating peptide with effects on sleep architecture (slow-wave sleep proportion) and stress buffering. Dihexa is a cognitive plasticity peptide with effects on dendritic spine formation and synaptic structure. They are mechanistically and operationally non-overlapping. The interesting overlap is the cognitive benefit channel: improved sleep quality from DSIP can support the consolidation of new synaptic connections, which is the substrate Dihexa creates. In this sense the two are complementary — Dihexa provides the structural plasticity, DSIP supports the sleep-dependent consolidation process. Memory consolidation occurs predominantly during slow-wave sleep, which DSIP modestly increases.

Stacking with Dihexa

DSIP stacks naturally with cognitive enhancers used during the day for users where sleep quality is a limiting factor. Common combinations: DSIP + Dihexa (cognitive plasticity by day, sleep consolidation at night), DSIP + magnesium glycinate at bedtime, DSIP + Glycine 3g pre-sleep, DSIP + low-dose melatonin (0.3-1 mg) for combined sleep onset and architecture support. The opioid-withdrawal protocols in the Russian literature use DSIP alongside standard withdrawal management. Avoid combining with benzodiazepines or Z-drugs without medical guidance (additive sedation). Effects of DSIP are subtle and incremental rather than dramatic; users expecting hypnotic-strength sleep induction will be disappointed.

Frequently Asked Questions

Not in the sense a benzodiazepine or zolpidem does. DSIP improves sleep quality and slow-wave proportion modestly rather than producing acute sedation. Some users notice no acute effect at all and only see results in next-morning recovery and mood.

Most users notice nothing immediately. Effects on sleep architecture build over a single night and may take 3-7 nights of consistent use to become subjectively noticeable.

It can be, but intermittent use (2-3 nights per week) is more commonly recommended to avoid tolerance development. The peptide has no documented dependence profile.

No. DSIP is not controlled, not scheduled, and not licensed as a medicine in the UK. It is sold as a research chemical for laboratory use.

Anecdotally yes — some users report DSIP helps reset disrupted circadian rhythm faster than melatonin alone. There is no formal clinical trial in jet lag specifically.

No published interaction data exists. The mechanisms are non-overlapping (sleep architecture vs synaptogenic plasticity) and there is no theoretical reason for adverse interaction. The combination is conceptually attractive given sleep's role in memory consolidation.

The Bottom Line

DSIP is the most-researched sleep-modulating peptide despite 45 years of inability to converge on a defined mechanism or achieve regulatory approval. Its effects are modest but real — improvements in slow-wave sleep proportion and stress buffering rather than acute hypnotic action. As a sleep-quality adjunct in a cognitive enhancement protocol, particularly one using Dihexa for synaptic plasticity, DSIP serves a defensible complementary role. Users seeking acute sleep induction should look elsewhere; users seeking better sleep architecture and subtle stress buffering are the right fit.